Near Normalisation of BG Improves the Potentiating Effect of GLP-1

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-02-29

Study Completion Date

2004-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The ability of glucagon-like peptide 1 to enhance beta-cell responsiveness to I.v. glucose is impaired in patients with type 2 diabetes mellitus compared with healthy individuals. We investigated whether 4 weeks of near-normalisation og blood glucose improves the potentiation of glucose-stimulated insulin secretion by GLP-1

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Beta-Cell Function After Near-Normalisation of Blood Glucose

NCT00612950

Type 2 Diabetes

COMPLETED NA

Glucagon-Like Peptide-1 (GLP-1) Suppression of Alpha Cell Secretion in Type 2 Diabetes Mellitus (T2DM)

NCT00862589

Hyperglycemia Hyperglucagonemia Glucose Intolerance

COMPLETED NA

The Effect of GLP-1 on the Inhibition of Glucagon Secretion

NCT01507597

Type 2 Diabetes Type 1 Diabetes

COMPLETED NA

Influence of Glucagon Inhibition in Relation to the Anti-Diabetic Effect of Glucagon-Like Peptide-1 (GLP-1) in Patients With Type 2 Diabetes Mellitus

NCT00655603

Type 2 Diabetes Mellitus

UNKNOWN NA

Effect of GLP-1 and GIP on Insulin Secretion in Type-1 Diabetes Mellitus

NCT00603031

Type-1 Diabetes Mellitus

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GLP-1

A graded glucose infusion with an infusion of GLP-1 (1½ pmol/kg/min)

Group Type EXPERIMENTAL

glucagon-like peptide-1

Intervention Type DRUG

continuous infusion of GLP-1 (1½ pmol/kg/min)

Saline

A graded glucose infusion together with a continuous infusion of saline

Group Type EXPERIMENTAL

Saline

Intervention Type DRUG

continuous infusion of saline

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

glucagon-like peptide-1

continuous infusion of GLP-1 (1½ pmol/kg/min)

Intervention Type DRUG

Saline

continuous infusion of saline

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-70 years
* Type 2 diabetes diagnosed after 30 years of age
* BMI \> 25

Exclusion Criteria

* Severe complications to diabetes
* Abnormal liver og kidney function
* Haemoglobin below the lower limit
* Macroalbuminuria
* Systemic disease
* Pregnancy

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes